Delivery Order SPE2DB22D1106-SPE2DB25FFGB6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Lisdexamfetamine 10 mg capsules (100-count units) with a ceiling value of $1,278.13. This competitively awarded, firm fixed-price delivery order is set to be completed by July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Lisdexamfetamine 40 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $1,137.22. This non-set-aside delivery order is scheduled for ultimate completion on August 19, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Lisdexamfetamine 10 mg capsules (100 count) with a ceiling value of $1,501.54. This firm fixed-price delivery order, which must be completed by July 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award carries no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Lisdexamfetamine 20 mg capsules (100-count units) with a ceiling value of $4,221.50. This competitively awarded, firm fixed-price delivery order is set to be completed by August 8, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 20 mg capsules (100 count) on August 28, 2025, with a ceiling value of $1,726.50 and a completion date of August 29, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.9 million and extends through December...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Lisdexamfetamine 50 mg capsules (100 count units) with a ceiling value of $2,047.19. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025, and represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. No set-aside designation was used for this award, indicating...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for Lisdexamfetamine 20 mg capsules (100-count units) with a ceiling value of $2,587.33. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The order is set to complete by July 25, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $1,437.63 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Lisdexamfetamine 10 mg capsules (90-count units). This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract involves no set-aside designation and was competitively awarded. Performance will occur...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Lisdexamfetamine 60 mg capsules (100-count units) with a ceiling value of $1,554.75. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The ultimate completion date for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,883.72 for Lisdexamfetamine 30 mg capsules (100-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order under the company's broader pharmaceutical supply arrangements with DLA. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFGB6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Lisdexamfetamine 20 mg capsules (100-count units) under a firm fixed-price contract valued at $11,279.96. This non-competitive delivery order is expected to be completed by September 2, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal vendor supplying medications and medical commodities to military and veteran healthcare systems. The company's established role as a prime vendor under the DLA's Medical Supply Chain enables it to fulfill diverse pharmaceutical procurement needs across multiple therapeutic domains. This delivery order for Lisdexamfetamine, a medication commonly prescribed for attention-deficit/hyperactivity disorder, reflects the ongoing pharmaceutical supply requirements across the Department of Defense healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.3k | 8/29/25 |